Core Viewpoint - The announcement highlights that Borui Pharmaceutical's subsidiary, Borui Medicine, has received approval from the National Medical Products Administration for clinical trials of BGM1812 injection, aimed at treating overweight or obesity [1] Group 1: Clinical Trial Approval - Borui Medicine has been granted a Clinical Trial Approval Notice for BGM1812 injection, a new long-acting Amylin analog designed for weight loss [1] - The drug has shown good molecular activity and pharmaceutical stability [1] - The FDA has already approved the clinical trial for BGM1812 injection in the United States, with the first patient enrolled [1] Group 2: Market Position - There are currently no similar targeted formulations approved for weight loss on the global market [1]